Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
39.21
-0.66 (-1.66%)
Aug 28, 2026, 4:00 PM EDT - Market closed
HRMY Revenue
Harmony Biosciences Holdings had revenue of $261.28M in the quarter ending June 30, 2026, with 30.32% growth. This brings the company's revenue in the last twelve months to $959.90M, up 24.25% year-over-year. In the year 2025, Harmony Biosciences Holdings had annual revenue of $868.45M with 21.51% growth.
Revenue (ttm)
$959.90M
Revenue Growth
+24.25%
P/S Ratio
2.38
Revenue / Employee
$3,276,102
Employees
293
Market Cap
2.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 868.45M | 153.72M | 21.51% |
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | 6.00M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Aurinia Pharmaceuticals | 311.51M |
| Nuvation Bio | 169.90M |
| Mesoblast | 120.25M |
| Ocular Therapeutix | 52.06M |
HRMY News
- 3 days ago - Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 days ago - Harmony Biosciences initiated with an Outperform at Wolfe Research - TheFly
- 17 days ago - Harmony Biosciences Holdings Transcript: Piper Sandler Virtual CNS Symposium - Transcripts
- 24 days ago - Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium - GlobeNewsWire
- 25 days ago - Harmony Biosciences price target raised to $34 from $29 at Truist - TheFly
- 25 days ago - Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank - TheFly
- 25 days ago - Harmony Biosciences price target raised to $37 from $33 at UBS - TheFly
- 25 days ago - Harmony Biosciences price target raised to $30 from $28 at BofA - TheFly